RxDoctor Payments Data

Faizi Ahmed, MD

Neurology · Tampa, FLNPI 1356572119

Payments from drug & device makers

$39,791in general payments, 2019–2025

Across 1,092 payments — averaging $36.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$15K
  • AbbVie$7K
  • Johnson & Johnson$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Vanda Pharmaceuticals Inc.$1K
  • plus $11K from 31 others

What the payments were for

  • Speaking & faculty fees$15,54139%
  • Travel & lodging$1,4914%
  • Food & beverage$22,35956%
  • Education$4001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,791 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$246,420
Medicare patients
83
Services billed
1,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl420$523,790
AuvelityDextromethorphan Hbr/Bupropion28$30,703
VyvanseLisdexamfetamine Dimesylate16$9,248
DayvigoLemborexant16$6,598
Clozapine43$3,516
Vilazodone Hcl30$3,126
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine59$2,674
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine80$2,453
Quetiapine Fumarate86$1,672
Aripiprazole36$1,358
Alprazolam152$1,307
Mirtazapine59$1,282
Methylphenidate Er (La)Methylphenidate Hcl13$1,212
Duloxetine Hcl50$1,140
Lamotrigine86$1,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$2,656$523,790420 claims
Axsome Therapeutics, Inc.Auvelity$897$30,70328 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$899$9,24816 claims
Eisai Inc.Dayvigo$749$6,59816 claims
Almatica Pharma LLCSertraline Hcl$412$18241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →